Overview

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy of different doses of nor UDCA vs. placebo for the treatment of Primary Sclerosing Cholangitis (PSC). Identification of optimal dose(s)for the treatment of PSC.
Phase:
Phase 2
Details
Lead Sponsor:
Dr. Falk Pharma GmbH